Optimized UPLC–MS/MS Method for the Quantitation of Olanzapine in Human Plasma: Application to a Bioequivalence study
Authors:
- 1 July 2019
- journal article
- research article
- Published by Taylor & Francis in Bioanalysis
- Vol. 11 (13) , 1291-1302
Abstract
Aim: Olanzapine (OLZ) is the first-line, cost-effectiveness treatment for schizophrenia in China. A quantitative ultrahigh performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for determination of OLZ in human plasma was developed. Results: LC separation was achieved on Waters XBrige C-18 column. ESI+ was involved and multiple reaction monitoring transitions were at m/z 313.2 -> 256.1 for OLZ and m/z 316.2 -> 256.1 IS (d3-OLZ). The linear range was 0.1-20 ng/ml with LLOQ of 0.1 ng/ml. Accuracy and precision were within 10%. The validated method was successfully applied to a bioequivalence study of OLZ disintegrating tablets at dose of 5 mg with 100% reproducibility evaluated by incurred sample reanalysis. Conclusion: A robust validated method was developed for quantitation of OLZ in human plasma.Keywords
This publication has 21 references indexed in Scilit:
- Application of an ultra-performance liquid chromatography method with tandem mass spectrometry to pharmacokinetics, tissue distribution and excretion in the study of DAT-230, a novel tubulin-binding agent candidate, in ratsJournal of Pharmaceutical and Biomedical Analysis, 2015
- Simultaneous quantification of olanzapine and its metabolite N‐desmethylolanzapine in human plasma by liquid chromatography tandem mass spectrometry for therapeutic drug monitoringBiomedical Chromatography, 2014
- Development and validation of an ultrafiltration-UPLC-MS/MS method for rapid quantification of unbound docetaxel in human plasmaJournal of Chromatography B, 2014
- Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC–MS/MS: Its pharmacokinetic applicationJournal of Pharmaceutical and Biomedical Analysis, 2014
- LC–MS/MS assay for olanzapine in human plasma and its application to a bioequivalence studyActa Pharmaceutica Sinica B, 2012
- System suitability in bioanalytical LC/MS/MSJournal of Pharmaceutical and Biomedical Analysis, 2007
- Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2006
- Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography–electrospray ionization mass spectrometryJournal of Chromatography B, 2004
- Direct‐injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N ‐desmethylclozapine in human plasmaRapid Communications in Mass Spectrometry, 2002
- OlanzapineClinical Pharmacokinetics, 1999